Actively Moving in Session: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares closed the most recent session at $114.280, moving +0.249%. The company shares touched $116.470 as the high point and dipped down to as low as $113.400. In comparing the current level to Intercept Pharmaceuticals, Inc.’s moving averages, the price sits -9.083% off its 50-day moving average of $126.010 and -21.503% away from the stock’s 200-day moving average which is $145.948.

A moving average is the average price of a stock over a given time frame. With price movements smoothed out, traders can more easily identify true trends and use them as potential indicators of future price levels. If the current stock price is above the moving average, the average can serve as a support point, keeping the stock price above it. On the other hand, if a stock is trading below a moving average, that average can also serve as a strong resistance, preventing the stock from breaking through it. 

Taking a longer term look at where the stock has been and where it’s headed, we note that currently the stock has traded in the range of $89.760 – 186.870 over the past 52-weeks. The latest bid places it $-72.305 away from the 52-week high of $186.870, or -38.693%. On the other end, the latest bid puts the equity $24.805 away from the 52-week low of $89.760, or +27.635%. The 52-week metric is serves as an important parameter for investors as they gauge the current price level of a stock and where it might be headed in the future.

Another important metric used by institutional and retail investors alike, is the analyst price target on a stock. Wall Street brokerage firms on the sell-side hire analysts to conduct research on stocks they cover for their clients. Analysts issue reports which often include a future stock price projection for the stock. Thomson Reuters’ First Call, which many consider to be the benchmark for EPS and consensus data, currently have the price target listed as $204.830. This is the consensus of all analyst targets from the brokerage firms polled by First Call.

The information provided on this website is for individual use only and should be considered strictly informational in nature. The article is not advice, and should not be treated as such. We are in no way responsible for any investment loss or damages. All content in our articles is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.

Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our articles. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors. 

COMMENTS